期刊文献+

过量误服甲磺酸伊马替尼治疗慢性粒细胞白血病达到遗传学缓解1例

下载PDF
导出
摘要 甲磺酸伊马替尼(商品名:格列卫)是慢性粒细胞白血病(chronic myelogenous leukemia,CML)的分子靶向性药物,对慢性粒细胞白血病慢性期患者剂量为400 mg/d,对急变期和加速期患者剂量为600 mg/d。我院收治的1例CML慢性期患者过量误服甲磺酸伊马替尼1200 mg/d,连续10 d。
出处 《第三军医大学学报》 CAS CSCD 北大核心 2011年第7期718-718,722,共2页 Journal of Third Military Medical University
  • 相关文献

参考文献5

  • 1National Comprehensive Cancer Network (2010). NCCN clinical practice guidelines in oncology-Chronic myelogenous leukemia, v. 2. 2010.
  • 2Mughal T I, Schrieber A. Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase [ J ]. Biologics, 2010, 4 : 315 - 323.
  • 3Peng B, Hayes M, Racine-Poon A, et al. Clinical investigation of the pharmacokinetic/phannacodynamic relationship for Glivec ( STI571 ) : a novel inhibitor of signal transduction[J]. Am Soc Clin Oncol, 2001,280.
  • 4Druker B J, Talpaz M, Resta D J, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leu- kemia[ J ]. N Engl J Med, 2001, 344 ( 14 ) : 1031 - 1037.
  • 5Cortes J E, Baccarani M, Guilhot F, et al. Phase Ⅲ, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study[J]. J Clin Oncol, 2010, 28 ( 3 ) : 424 - 430.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部